Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tarsus Pharmaceuticals, Inc. (TARS)
USD55.43
-0.68 (-1.21%)
US NASDAQ Healthcare Biotechnology
Address
15440 Laguna Canyon Road 92618
Irvine, CA, US
Irvine, CA, US
CEO
Bobak R. Azamian
Website
tarsusrx.com
IPO
2020-10-16
CIK 1819790 ISIN US87650L1035
Description
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
News Sentiment (7d)
4 articles
- Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 GlobeNewsWire
- All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy Zacks Investment Research
- Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug Benzinga
- Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript Seeking Alpha
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD55.43
-0.68 (-1.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
722.5K
Beta
0.51
Float Shares
39.86M
Free Float %
93.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.30% | -6.46% | -17.65% | -1.56% | -17.51% | -26.93% | +44.31% | +261.29% | +101.99% | +190.72% | +190.72% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
55.43
Low
68.00
+22.7%
Consensus
89.33
+61.2%
Median
100.00
+80.4%
High
100.00
+80.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 5 |
81.40
+46.9%
|
| All Time | 11 |
73.36
+32.3%
|
Quality scores
Altman Z-Score
7.26
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+146.7% ★ Q1'26: +106.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+48.2% ★ Q1'26: +75.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-11.5% Q1'26: -18.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-12.3% Q1'26: -3.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-280.0% Q1'26: -37.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+11.1% Q1'26: +9.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.75× Q1'26: -3.90× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
57.03M
est: 49.07M (+16.2%)
|
25.82M
est: 25.86M (-0.2%)
|
17.45M
est: 42.56M (-59.0%)
|
182.95M
est: 175.34M (+4.3%)
|
451.36M
est: 444.10M (+1.6%)
|
694.42M
680.28M – 706.94M
+56.4% YoY
|
904.10M
897.71M – 910.50M
+30.2% YoY
|
1.07B
1.07B – 1.08B
+18.5% YoY
|
1.20B
1.17B – 1.24B
+11.9% YoY
|
1.33B
1.29B – 1.38B
+10.8% YoY
|
| EBITDA |
-13.46M
est: -17.84M (+24.6%)
|
-59.71M
est: -9.40M (-535.1%)
|
-131.67M
est: -25.00M (-426.7%)
|
-106.48M
est: -102.99M (-3.4%)
|
-53.61M
est: -260.85M (+79.4%)
|
-407.88M
-415.23M – -399.57M
-56.4% YoY
|
-531.04M
-534.79M – -527.28M
-30.2% YoY
|
-629.32M
-632.39M – -626.26M
-18.5% YoY
|
-704.44M
-729.52M – -685.19M
-11.9% YoY
|
-780.34M
-808.12M – -759.01M
-10.8% YoY
|
| EBIT |
-13.77M
est: -17.96M (+23.3%)
|
-60.03M
est: -9.46M (-534.3%)
|
-132.55M
est: -25.14M (-427.3%)
|
-107.71M
est: -103.56M (-4.0%)
|
-55.42M
est: -262.28M (+78.9%)
|
-410.13M
-417.52M – -401.77M
-56.4% YoY
|
-533.96M
-537.74M – -530.18M
-30.2% YoY
|
-632.79M
-635.88M – -629.71M
-18.5% YoY
|
-708.33M
-733.54M – -688.97M
-11.9% YoY
|
-784.64M
-812.57M – -763.19M
-10.8% YoY
|
| Net Income |
-13.83M
est: -21.53M (+35.8%)
|
-62.09M
est: -88.87M (+30.1%)
|
-135.89M
est: -198.49M (+31.5%)
|
-115.55M
est: -134.04M (+13.8%)
|
-66.42M
est: -67.22M (+1.2%)
|
-34.06M
-43.08M – -20.69M
+49.3% YoY
|
153.73M
90.49M – 169.73M
+551.4% YoY
|
189.19M
125.17M – 253.21M
+23.1% YoY
|
264.28M
254.89M – 276.51M
+39.7% YoY
|
350.15M
337.71M – 366.35M
+32.5% YoY
|
| SGA |
25.40M
est: 105.14M (-75.8%)
|
44.95M
est: 55.40M (-18.9%)
|
108.70M
est: 90.75M (+19.8%)
|
237.31M
est: 373.85M (-36.5%)
|
427.32M
est: 946.87M (-54.9%)
|
1.48B
1.45B – 1.51B
+56.4% YoY
|
1.93B
1.91B – 1.94B
+30.2% YoY
|
2.28B
2.27B – 2.30B
+18.5% YoY
|
2.56B
2.49B – 2.65B
+11.9% YoY
|
2.83B
2.76B – 2.93B
+10.8% YoY
|
| EPS |
-0.67
est: -0.57 (-17.0%)
|
-2.52
est: -2.36 (-6.6%)
|
-4.62
est: -4.70 (+1.7%)
|
-3.07
est: -3.22 (+4.6%)
|
-1.59
est: -1.43 (-11.3%)
|
-0.71
-1.03 – -0.50
+50.5% YoY
|
2.95
2.17 – 4.06
+517.0% YoY
|
4.74
3.00 – 6.06
+60.7% YoY
|
6.33
6.10 – 6.62
+33.4% YoY
|
8.38
8.08 – 8.77
+32.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.07M
OE per share TTM
-0.42
Owner's Yield
-0.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
114.70M
Insider transactions (90d)
1
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vivo Capital IX, LLC | 3.25M | 16.20% | 3.25M | — | 3.25M | — | OO | Delaware | 2020-10-28 | ↗ |
| 2 | RTW Investments, LP | 2.46M | 12.13% | — | 2.46M | — | 2.46M | IA, PN, OO | A | 2021-02-12 | ↗ |
| 3 | Roderick Wong | 2.46M | 12.13% | — | 2.46M | — | 2.46M | HC, IN | A | 2021-02-12 | ↗ |
| 4 | Horowitz Limited Partnership VIII | 1.99M | 10.30% | 1.92M | 66.2K | 1.92M | 66.2K | PN | — | 2020-10-30 | ↗ |
| 5 | Jason E. Tester | 1.95M | 10.10% | 28.4K | 1.92M | 28.4K | 1.92M | IN | — | 2020-10-30 | ↗ |
| 6 | Morgan Stanley | 1.94M | 5.90% | 13.00 | 1.94M | — | 1.94M | HC, CO | — | 2024-02-09 | ↗ |
| 7 | Paradigm BioCapital Advisors GP LLC | 1.93M | 5.80% | 1.93M | — | 1.93M | — | OO | Delaware | 2024-01-22 | ↗ |
| 8 | Paradigm BioCapital Advisors LP | 1.93M | 5.80% | 1.93M | — | 1.93M | — | PN | Delaware | 2024-01-22 | ↗ |
| 9 | Senai Asefaw, M.D. | 1.93M | 5.80% | 1.93M | — | 1.93M | — | IN | Delaware | 2024-01-22 | ↗ |
| 10 | Horowitz Management, Inc. | 1.92M | 10.00% | 1.92M | — | 1.92M | — | CO | — | 2020-10-30 | ↗ |
| 11 | FHMLS IX, L.L.C. | 1.92M | 9.50% | — | 1.92M | — | 1.92M | OO | Delaware | 2020-10-23 | ↗ |
| 12 | FHMLS IX, L.P. | 1.92M | 9.50% | — | 1.92M | — | 1.92M | PN | Delaware | 2020-10-23 | ↗ |
| 13 | Frazier Life Sciences IX, L.P. | 1.92M | 9.50% | — | 1.92M | — | 1.92M | PN | Delaware | 2020-10-23 | ↗ |
| 14 | James Topper | 1.92M | 9.50% | — | 1.92M | — | 1.92M | IN | Delaware | 2020-10-23 | ↗ |
| 15 | Patrick Heron | 1.92M | 9.50% | — | 1.92M | — | 1.92M | IN | Delaware | 2020-10-23 | ↗ |
| 16 | Bobak Azamian | 1.92M | 9.04% | 1.92M | — | 1.92M | — | IN | — | 2021-02-12 | ↗ |
| 17 | Paradigm BioCapital International Fund Ltd. | 1.64M | 5.00% | 1.64M | — | 1.64M | — | CO | Delaware | 2024-01-22 | ↗ |
| 18 | RTW Master Fund, Ltd. | 1.58M | 7.78% | — | 1.58M | — | 1.58M | CO | A | 2021-02-12 | ↗ |
| 19 | 20-1665304 | 1.43M | 5.36% | 1.43M | — | 1.43M | — | IA | Delaware | 2023-02-03 | ↗ |
| 20 | Bihua Chen | 1.40M | 6.79% | — | 1.40M | — | 1.40M | IN | United States | 2022-02-14 | ↗ |
| 21 | Cormorant Asset Management, LP | 1.40M | 6.79% | — | 1.40M | — | 1.40M | PN | Delaware | 2022-02-14 | ↗ |
| 22 | (1) BlackRock, Inc. | 1.33M | 4.90% | 1.30M | — | 1.33M | — | HC | Delaware | 2023-02-09 | ↗ |
| 23 | Company, L.P. | 1.32M | 5.04% | — | 1.32M | — | — | PN | United States | 2022-05-11 | ↗ |
| 24 | Deerfield Mgmt, L.P. | 1.32M | 5.04% | — | 1.32M | — | — | PN | United States | 2022-05-11 | ↗ |
| 25 | Deerfield Partners, L.P. | 1.32M | 5.04% | — | 1.32M | — | — | PN | United States | 2022-05-11 | ↗ |
| 26 | James E. Flynn | 1.32M | 5.04% | — | 1.32M | — | — | IN | United States | 2022-05-11 | ↗ |
| 27 | 2 | 1.30M | 6.40% | — | 1.30M | — | 1.30M | IA | Delaware | 2021-02-16 | ↗ |
| 28 | Joseph Edelman | 1.30M | 6.40% | — | 1.30M | — | 1.30M | IN | Delaware | 2021-02-16 | ↗ |
| 29 | Michael Ackermann | 1.26M | 6.10% | 1.26M | — | 1.26M | — | IN | — | 2022-02-14 | ↗ |
| 30 | Flying L Investments XI, LLC | 1.21M | 5.88% | 1.21M | — | 1.21M | — | OO | — | 2021-02-16 | ↗ |
| 31 | Cormorant Global Healthcare GP, LLC | 764.6K | 3.70% | — | 764.6K | — | 764.6K | OO | Delaware | 2022-02-14 | ↗ |
| 32 | Cormorant Global Healthcare Master Fund, LP | 764.6K | 3.70% | — | 764.6K | — | 764.6K | PN | Cayman Islands | 2022-02-14 | ↗ |
| 33 | Cormorant Private Healthcare Fund III, LP | 351.8K | 1.70% | — | 351.8K | — | 351.8K | PN | Delaware | 2022-02-14 | ↗ |
| 34 | Cormorant Private Healthcare GP III, LLC | 351.8K | 1.70% | — | 351.8K | — | 351.8K | OO | Delaware | 2022-02-14 | ↗ |
| 35 | Cormorant Private Healthcare Fund II, LP | 281.4K | 1.36% | — | 281.4K | — | 281.4K | PN | Delaware | 2022-02-14 | ↗ |
| 36 | Cormorant Private Healthcare GP II, LLC | 281.4K | 1.36% | — | 281.4K | — | 281.4K | OO | Delaware | 2022-02-14 | ↗ |
| 37 | Adam S. Horowitz Revocable Trust | 66.2K | 0.30% | 66.2K | — | 66.2K | — | OO | — | 2020-10-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-215 vs prev Q
New positions
5
Closed positions
216
Increased
21
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 584.7K +584.7K (+100.0%) | 47.87B +47.9B (+100.0%) | 1.37% +1.372 pp | 0.07% +0.072 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 3.79M +10.9K (+0.3%) | 310.37M +85.7M (+38.2%) | 8.90% -0.026 pp | 0.01% +0.001 pp | USD34.31 +138.6% | 6 qtrs — |
| 3 | RTW INVESTMENTS, LP | 3.34M +157.9K (+5.0%) | 273.10M +84.3M (+44.6%) | 7.83% +0.327 pp | 2.74% +0.409 pp | USD35.75 +129.0% | 21 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 3.00M +4.0K (+0.1%) | 245.97M +67.7M (+38.0%) | 7.05% -0.032 pp | 4.39% -0.590 pp | USD53.80 +52.2% | 4 qtrs — |
| 5 | PARADIGM BIOCAPITAL ADVISORS LP | 2.56M -103.5K (-3.9%) | 209.79M +51.4M (+32.4%) | 6.01% -0.280 pp | 5.35% +0.849 pp | USD32.86 +149.2% | 9 qtrs — |
| 6 | VANGUARD GROUP INC | 2.40M +127.5K (+5.6%) | 196.48M +61.4M (+45.5%) | 5.63% +0.268 pp | 0.00% +0.001 pp | USD29.50 +177.6% | 21 qtrs — |
| 7 | JENNISON ASSOCIATES LLC | 2.23M -374.5K (-14.4%) | 182.60M +27.8M (+18.0%) | 5.23% -0.915 pp | 0.11% +0.020 pp | USD38.25 +114.1% | 8 qtrs — |
| 8 | MORGAN STANLEY | 2.04M +128.3K (+6.7%) | 167.10M +53.4M (+47.0%) | 4.79% +0.275 pp | 0.01% +0.003 pp | USD28.93 +183.0% | 21 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 1.93M +491.3K (+34.1%) | 158.06M +72.5M (+84.8%) | 4.53% +1.133 pp | 0.07% +0.032 pp | USD53.29 +53.6% | 8 qtrs — |
| 10 | TANG CAPITAL MANAGEMENT LLC | 1.19M -1.3M (-51.6%) | 97.32M -48.6M (-33.3%) | 2.79% -3.005 pp | 4.81% -0.808 pp | USD18.85 +334.4% | 16 qtrs — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.17M +141.4K (+13.7%) | 96.00M +34.7M (+56.7%) | 2.75% +0.318 pp | 0.65% +0.213 pp | USD54.64 +49.9% | 4 qtrs — |
| 12 | ASSENAGON ASSET MANAGEMENT S.A. | 1.13M -120.2K (-9.6%) | 92.34M +18.2M (+24.5%) | 2.65% -0.299 pp | 0.13% +0.026 pp | USD34.85 +134.9% | 7 qtrs — |
| 13 | INVESCO LTD. | 1.01M +75.4K (+8.0%) | 82.89M +27.2M (+48.9%) | 2.38% +0.164 pp | 0.01% +0.004 pp | USD41.01 +99.7% | 21 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 947.8K +3.3K (+0.3%) | 77.62M +21.5M (+38.3%) | 2.22% -0.005 pp | 0.00% +0.001 pp | USD26.56 +208.3% | 21 qtrs — |
| 15 | STATE STREET CORP | 929.1K -7.1K (-0.8%) | 76.07M +20.4M (+36.7%) | 2.18% -0.030 pp | 0.00% +0.001 pp | USD25.22 +224.7% | 21 qtrs — |
| 16 | LORD, ABBETT & CO. LLC | 855.6K -130.0K (-13.2%) | 70.06M +11.5M (+19.6%) | 2.01% -0.319 pp | 0.22% +0.041 pp | USD44.03 +86.0% | 8 qtrs — |
| 17 | BANK OF AMERICA CORP /DE/ | 758.1K +222.1K (+41.4%) | 62.07M +30.2M (+94.9%) | 1.78% +0.514 pp | 0.00% +0.002 pp | USD51.16 +60.0% | 21 qtrs — |
| 18 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 728.6K -438.9K (-37.6%) | 59.66M -9.7M (-14.0%) | 1.71% -1.046 pp | 1.60% -0.477 pp | USD16.36 +400.5% | 16 qtrs — |
| 19 | FMR LLC | 647.1K +625.3K (+2,860.1%) | 52.99M +51.7M (+3,978.3%) | 1.52% +1.467 pp | 0.00% +0.003 pp | USD80.86 +1.3% | 16 qtrs — |
| 20 | D. E. SHAW & CO., INC. | 615.2K +16.8K (+2.8%) | 50.37M +14.8M (+41.7%) | 1.44% +0.031 pp | 0.03% +0.008 pp | USD43.75 +87.2% | 12 qtrs — |
| 21 | PRICE T ROWE ASSOCIATES INC /MD/ | 518.8K +65.9K (+14.6%) | 42.48M +15.6M (+57.8%) | 1.22% +0.149 pp | 0.00% +0.002 pp | USD51.78 +58.1% | 8 qtrs — |
| 22 | TORONTO DOMINION BANK | 510.3K -107.3K (-17.4%) | 41.78M +5.1M (+13.8%) | 1.20% -0.260 pp | 0.06% +0.005 pp | USD55.37 +47.9% | 5 qtrs — |
| 23 | CLEARBRIDGE INVESTMENTS, LLC | 506.1K -60.9K (-10.7%) | 41.44M +7.7M (+23.0%) | 1.19% -0.151 pp | 0.03% +0.008 pp | USD44.60 +83.6% | 3 qtrs — |
| 24 | ENSIGN PEAK ADVISORS, INC | 474.1K -8.3K (-1.7%) | 38.82M +10.1M (+35.4%) | 1.11% -0.026 pp | 0.07% +0.022 pp | USD31.72 +158.1% | 21 qtrs — |
| 25 | LOOMIS SAYLES & CO L P | 441.9K +52.0K (+13.3%) | 36.18M +13.0M (+56.1%) | 1.04% +0.117 pp | 0.04% +0.016 pp | USD62.07 +31.9% | 2 qtrs — |
| 26 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 436.6K -121.8K (-21.8%) | 35.75M +2.6M (+7.7%) | 1.02% -0.293 pp | 0.05% +0.006 pp | USD26.72 +206.4% | 10 qtrs — |
| 27 | QUBE RESEARCH & TECHNOLOGIES LTD | 401.2K -121.0K (-23.2%) | 32.85M +1.8M (+5.8%) | 0.94% -0.291 pp | 0.03% +0.001 pp | USD45.40 +80.4% | 9 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 378.7K +37.7K (+11.1%) | 31.01M +10.7M (+53.0%) | 0.89% +0.084 pp | 0.00% +0.001 pp | USD35.95 +127.8% | 20 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 356.1K +151.8K (+74.3%) | 29.16M +17.0M (+140.1%) | 0.84% +0.354 pp | 0.01% +0.007 pp | USD63.27 +29.4% | 5 qtrs — |
| 30 | NORTHERN TRUST CORP | 342.5K -15.6K (-4.4%) | 28.04M +6.8M (+31.8%) | 0.80% -0.042 pp | 0.00% +0.001 pp | USD28.99 +182.4% | 21 qtrs — |
| 31 | FRANKLIN RESOURCES INC | 337.0K +314.8K (+1,419.3%) | 27.59M +26.3M (+1,993.2%) | 0.79% +0.739 pp | 0.01% +0.006 pp | USD79.21 +3.4% | 7 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 333.1K +199.0 (+0.1%) | 27.28M +7.5M (+37.9%) | 0.78% -0.004 pp | 0.00% +0.001 pp | USD26.68 +206.9% | 21 qtrs — |
| 33 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 332.4K +64.9K (+24.3%) | 27.22M +11.3M (+71.2%) | 0.78% +0.149 pp | 0.41% +0.183 pp | USD63.82 +28.3% | 2 qtrs — |
| 34 | BIOIMPACT CAPITAL LLC | 328.9K -12.6K (-3.7%) | 26.93M +6.6M (+32.7%) | 0.77% -0.034 pp | 3.08% -0.241 pp | USD40.51 +102.1% | 3 qtrs — |
| 35 | NUVEEN, LLC | 322.5K -8.2K (-2.5%) | 26.41M +6.8M (+34.4%) | 0.76% -0.024 pp | 0.01% +0.002 pp | USD49.04 +67.0% | 4 qtrs — |
| 36 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 260.3K -28.0K (-9.7%) | 21.32M +4.2M (+24.4%) | 0.61% -0.070 pp | 1.09% +0.092 pp | USD51.99 +57.5% | 5 qtrs — |
| 37 | CORMORANT ASSET MANAGEMENT, LP | 250.0K -50.0K (-16.7%) | 20.47M +2.6M (+14.8%) | 0.59% -0.122 pp | 0.95% -0.284 pp | USD26.23 +212.2% | 21 qtrs — |
| 38 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 200.0K -50.0K (-20.0%) | 16.38M +1.5M (+10.2%) | 0.47% -0.121 pp | 0.81% -0.192 pp | USD38.45 +113.0% | 9 qtrs — |
| 39 | JANE STREET GROUP, LLC | 184.3K +184.3K (+100.0%) | 15.09M +15.1M (+100.0%) | 0.43% +0.433 pp | 0.00% +0.002 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 40 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 173.3K +69.5K (+66.9%) | 14.19M +8.0M (+130.0%) | 0.41% +0.162 pp | 0.04% +0.018 pp | USD61.82 +32.4% | 3 qtrs — |
| 41 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 161.8K +61.8K (+61.8%) | 13.25M +7.3M (+123.0%) | 0.38% +0.144 pp | 0.02% +0.011 pp | USD68.01 +20.4% | 2 qtrs — |
| 42 | ORBIMED ADVISORS LLC | 154.4K -43.5K (-22.0%) | 12.64M +881.1K (+7.5%) | 0.36% -0.105 pp | 0.26% -0.018 pp | USD51.37 +59.4% | 4 qtrs — |
| 43 | RUSSELL INVESTMENTS GROUP, LTD. | 153.8K +5.4K (+3.7%) | 12.59M +3.8M (+42.8%) | 0.36% +0.011 pp | 0.01% +0.004 pp | USD51.58 +58.7% | 12 qtrs — |
| 44 | CANADA PENSION PLAN INVESTMENT BOARD | 151.1K +19.8K (+15.1%) | 12.37M +4.6M (+58.6%) | 0.35% +0.045 pp | 0.01% +0.003 pp | USD61.99 +32.1% | 7 qtrs — |
| 45 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 130.4K +1.6K (+1.3%) | 10.53M +3.1M (+42.7%) | 0.31% +0.002 pp | 0.02% +0.005 pp | USD21.19 +286.4% | 17 qtrs — |
| 46 | JUMP FINANCIAL, LLC | 128.1K -137.9K (-51.8%) | 10.49M -5.3M (-33.7%) | 0.30% -0.327 pp | 0.13% -0.060 pp | USD44.56 +83.8% | 8 qtrs — |
| 47 | WELLS FARGO & COMPANY/MN | 119.1K +20.3K (+20.6%) | 9.75M +3.9M (+66.1%) | 0.28% +0.046 pp | 0.00% +0.001 pp | USD46.58 +75.8% | 21 qtrs — |
| 48 | JEFFERIES FINANCIAL GROUP INC. | 118.8K +5.7K (+5.1%) | 9.73M +3.0M (+44.8%) | 0.28% +0.012 pp | 0.05% +0.018 pp | USD33.06 +147.7% | 13 qtrs — |
| 49 | DEUTSCHE BANK AG\ | 118.2K -66.2K (-35.9%) | 9.68M -1.3M (-11.7%) | 0.28% -0.158 pp | 0.00% -0.001 pp | USD50.20 +63.1% | 21 qtrs — |
| 50 | NORGES BANK | 117.6K +117.6K (+100.0%) | 9.63M +9.6M (+100.0%) | 0.28% +0.276 pp | 0.00% +0.001 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 51 | MILLENNIUM MANAGEMENT LLC | 117.0K +16.4K (+16.3%) | 9.58M +3.6M (+60.3%) | 0.27% +0.037 pp | 0.00% +0.002 pp | USD55.78 +46.8% | 12 qtrs — |
| 52 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 114.5K -7.9K (-6.4%) | 9.37M +2.1M (+28.9%) | 0.27% -0.020 pp | 0.10% +0.022 pp | USD33.07 +147.6% | 6 qtrs — |
| 53 | FIRST TRUST ADVISORS LP | 111.8K +59.9K (+115.4%) | 9.15M +6.1M (+196.7%) | 0.26% +0.140 pp | 0.01% +0.004 pp | USD62.67 +30.7% | 3 qtrs — |
| 54 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 109.9K +18.3K (+19.9%) | 9.00M +3.6M (+65.3%) | 0.26% +0.042 pp | 0.01% +0.006 pp | USD57.75 +41.8% | 4 qtrs — |
| 55 | BANK OF NEW YORK MELLON CORP | 107.8K -1.6K (-1.5%) | 8.82M +2.3M (+35.7%) | 0.25% -0.005 pp | 0.00% +0.000 pp | USD27.01 +203.1% | 21 qtrs — |
| 56 | WOODLINE PARTNERS LP | 100.2K +— (+0.0%) | 8.20M +2.2M (+37.8%) | 0.24% -0.001 pp | 0.03% +0.004 pp | USD40.61 +101.6% | 6 qtrs — |
| 57 | CAPTION MANAGEMENT, LLC | 100.0K +85.4K (+584.9%) | 8.19M +7.3M (+843.7%) | 0.23% +0.200 pp | 0.06% +0.049 pp | USD78.60 +4.2% | 2 qtrs — |
| 58 | SANDS CAPITAL VENTURES, LLC | 85.0K -85.0K (-50.0%) | 6.96M -3.1M (-31.1%) | 0.20% -0.202 pp | 1.34% -0.871 pp | USD21.55 +280.0% | 18 qtrs — |
| 59 | BARCLAYS PLC | 80.8K -17.9K (-18.1%) | 6.61M +3.4M (+103.8%) | 0.19% -0.043 pp | 0.00% +0.001 pp | USD36.04 +127.2% | 16 qtrs — |
| 60 | — | 80.0K +80.0K (+100.0%) | 6.55M +6.6M (+100.0%) | 0.19% +0.188 pp | 2.78% +2.776 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 61 | VOLEON CAPITAL MANAGEMENT LP | 77.4K +54.4K (+236.7%) | 6.34M +5.0M (+363.8%) | 0.18% +0.127 pp | 0.14% +0.103 pp | USD75.21 +8.9% | 2 qtrs — |
| 62 | EAM INVESTORS, LLC | 72.9K +72.9K (+100.0%) | 5.97M +6.0M (+100.0%) | 0.17% +0.171 pp | 0.67% +0.665 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 63 | COMMONWEALTH EQUITY SERVICES, LLC | 68.3K +1.3K (+2.0%) | 5.59M +1.6M (+40.5%) | 0.16% +0.002 pp | 0.01% +0.002 pp | USD50.87 +61.0% | 4 qtrs — |
| 64 | UBS GROUP AG | 66.9K -51.7K (-43.6%) | 5.48M -1.6M (-22.3%) | 0.16% -0.123 pp | 0.00% 0.000 pp | USD53.83 +52.1% | 21 qtrs — |
| 65 | UBS ASSET MANAGEMENT AMERICAS INC | 66.3K +3.7K (+6.0%) | 5.43M +1.7M (+46.0%) | 0.16% +0.008 pp | 0.00% +0.000 pp | USD39.08 +109.5% | 8 qtrs — |
| 66 | LISANTI CAPITAL GROWTH, LLC | 64.3K +21.3K (+49.6%) | 5.27M +2.7M (+106.1%) | 0.15% +0.050 pp | 1.25% +0.623 pp | USD57.72 +41.9% | 6 qtrs — |
| 67 | RENAISSANCE TECHNOLOGIES LLC | 64.1K +22.5K (+54.1%) | 5.25M +2.8M (+112.3%) | 0.15% +0.052 pp | 0.01% +0.005 pp | USD67.31 +21.6% | 2 qtrs — |
| 68 | TD ASSET MANAGEMENT INC | 64.0K +11.3K (+21.5%) | 5.24M +2.1M (+67.4%) | 0.15% +0.026 pp | 0.00% +0.002 pp | USD53.50 +53.0% | 8 qtrs — |
| 69 | PDT PARTNERS, LLC | 63.0K +— (+0.0%) | 5.16M +1.4M (+37.8%) | 0.15% -0.001 pp | 0.33% +0.099 pp | USD40.51 +102.1% | 3 qtrs — |
| 70 | SWISS NATIONAL BANK | 62.4K +1.3K (+2.1%) | 5.11M +1.5M (+40.7%) | 0.15% +0.002 pp | 0.00% +0.001 pp | USD24.48 +234.5% | 13 qtrs — |
| 71 | JPMORGAN CHASE & CO | 56.6K -20.5K (-26.6%) | 4.64M +50.8K (+1.1%) | 0.13% -0.049 pp | 0.00% +0.000 pp | USD38.94 +110.3% | 21 qtrs — |
| 72 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 55.3K +1.3K (+2.4%) | 4.54M +1.3M (+41.5%) | 0.13% +0.002 pp | 0.00% +0.001 pp | USD40.98 +99.8% | 9 qtrs — |
| 73 | TREXQUANT INVESTMENT LP | 54.5K +34.5K (+172.7%) | 4.47M +3.3M (+275.7%) | 0.13% +0.081 pp | 0.04% +0.028 pp | USD66.71 +22.7% | 3 qtrs — |
| 74 | HIGHVISTA STRATEGIES LLC | 53.6K +28.7K (+115.5%) | 4.39M +2.9M (+196.9%) | 0.13% +0.067 pp | 1.13% +0.767 pp | USD67.34 +21.6% | 3 qtrs — |
| 75 | CITIGROUP INC | 52.0K +11.4K (+28.0%) | 4.26M +1.8M (+76.4%) | 0.12% +0.026 pp | 0.00% +0.001 pp | USD52.07 +57.2% | 21 qtrs — |
| 76 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 51.5K +51.5K (+100.0%) | 4.22M +4.2M (+100.0%) | 0.12% +0.121 pp | 0.03% +0.033 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 77 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 50.0K +50.0K (+100.0%) | 4.09M +4.1M (+100.0%) | 0.12% +0.117 pp | 0.01% +0.014 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 78 | FEDERATED HERMES, INC. | 49.3K +34.1K (+223.6%) | 4.04M +3.1M (+345.8%) | 0.12% +0.080 pp | 0.01% +0.005 pp | USD73.66 +11.2% | 8 qtrs — |
| 79 | RHUMBLINE ADVISERS | 47.1K -9.4K (-16.7%) | 3.85M +495.7K (+14.8%) | 0.11% -0.023 pp | 0.00% +0.000 pp | USD22.49 +264.1% | 15 qtrs — |
| 80 | BAIRD FINANCIAL GROUP, INC. | 46.9K -7.0K (-12.9%) | 3.84M +640.5K (+20.0%) | 0.11% -0.017 pp | 0.01% +0.001 pp | USD35.39 +131.4% | 8 qtrs — |
| 81 | ALGERT GLOBAL LLC | 46.0K +46.0K (+100.0%) | 3.77M +3.8M (+100.0%) | 0.11% +0.108 pp | 0.06% +0.059 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 82 | SEI INVESTMENTS CO | 43.3K +11.8K (+37.3%) | 3.55M +1.7M (+89.0%) | 0.10% +0.027 pp | 0.00% +0.002 pp | USD49.70 +64.7% | 10 qtrs — |
| 83 | NEW YORK STATE COMMON RETIREMENT FUND | 43.2K -5.5K (-11.2%) | 3.53M +644.8K (+22.3%) | 0.10% -0.014 pp | 0.00% +0.001 pp | USD30.01 +172.8% | 21 qtrs — |
| 84 | CAXTON ASSOCIATES LLP | 41.0K +41.0K (+100.0%) | 3.35M +3.4M (+100.0%) | 0.10% +0.096 pp | 0.07% +0.066 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 85 | ALLIANCEBERNSTEIN L.P. | 40.7K -300.0 (-0.7%) | 3.33M +894.9K (+36.8%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD26.48 +209.2% | 11 qtrs — |
| 86 | WALLEYE CAPITAL LLC | 40.3K +30.8K (+324.7%) | 3.30M +2.7M (+485.1%) | 0.09% +0.072 pp | 0.01% +0.008 pp | USD72.14 +13.5% | 3 qtrs — |
| 87 | F/M INVESTMENTS LLC | 39.2K +39.2K (+100.0%) | 3.21M +3.2M (+100.0%) | 0.09% +0.092 pp | 0.12% +0.122 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 88 | VOYA INVESTMENT MANAGEMENT LLC | 38.1K +6.1K (+19.0%) | 3.12M +1.2M (+63.9%) | 0.09% +0.014 pp | 0.00% +0.001 pp | USD48.13 +70.1% | 9 qtrs — |
| 89 | POINT72 ASSET MANAGEMENT, L.P. | 37.6K +37.6K (+100.0%) | 3.08M +3.1M (+100.0%) | 0.09% +0.088 pp | 0.00% +0.003 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 90 | PICTET ASSET MANAGEMENT HOLDING SA | 37.6K -36.1K (-49.0%) | 3.08M -1.2M (-28.1%) | 0.09% -0.086 pp | 0.00% -0.001 pp | USD51.61 +58.7% | 5 qtrs — |
| 91 | SILVERARC CAPITAL MANAGEMENT, LLC | 36.1K +36.1K (+100.0%) | 2.96M +3.0M (+100.0%) | 0.08% +0.085 pp | 0.41% +0.411 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 92 | RAYMOND JAMES FINANCIAL INC | 35.6K -13.7K (-27.7%) | 2.92M -13.3K (-0.5%) | 0.08% -0.033 pp | 0.00% +0.000 pp | USD48.39 +69.2% | 5 qtrs — |
| 93 | ALPS ADVISORS INC | 34.8K +13.3K (+62.0%) | 2.85M +1.6M (+123.2%) | 0.08% +0.031 pp | 0.02% +0.010 pp | USD44.87 +82.5% | 13 qtrs — |
| 94 | CALAMOS ADVISORS LLC | 34.4K +34.4K (+100.0%) | 2.82M +2.8M (+100.0%) | 0.08% +0.081 pp | 0.01% +0.011 pp | USD81.88 +0.0% | 1 qtrs NEW |
| 95 | E. OHMAN J:OR ASSET MANAGEMENT AB | 33.3K -5.0K (-13.0%) | 2.73M +451.0K (+19.8%) | 0.08% -0.012 pp | 0.06% +0.010 pp | USD36.57 +123.9% | 8 qtrs — |
| 96 | STATE OF WISCONSIN INVESTMENT BOARD | 31.9K +332.0 (+1.1%) | 2.61M +736.2K (+39.2%) | 0.07% +0.000 pp | 0.01% +0.002 pp | USD36.89 +122.0% | 13 qtrs — |
| 97 | IKARIAN CAPITAL, LLC | 31.2K -42.5K (-57.7%) | 2.55M -1.8M (-41.7%) | 0.07% -0.101 pp | 0.20% -0.243 pp | USD25.43 +222.0% | 10 qtrs — |
| 98 | LEGAL & GENERAL GROUP PLC | 31.1K -215.0 (-0.7%) | 2.55M +685.3K (+36.8%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD26.57 +208.2% | 21 qtrs — |
| 99 | LOS ANGELES CAPITAL MANAGEMENT LLC | 31.5K -5.6K (-15.1%) | 2.17M -33.2K (-1.5%) | 0.07% -0.014 pp | 0.01% 0.000 pp | USD47.43 +72.6% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 107 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Pharmaceuticals ETF PJP | 2.54% | 9.10M | 0.57% |
| 2 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.52% | 7.15M | 0.35% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 1.27% | 2.71M | 0.50% |
| 4 | Virtus Biotech ETF BBP | 1.21% | 1.19M | 0.34% |
| 5 | Harbor Human Capital Factor US Small Cap ETF HAPS | 1.01% | 1.72M | 0.61% |
| 6 | iShares U.S. Pharmaceuticals ETF IHE | 0.52% | 6.94M | 0.38% |
| 7 | First Trust Nasdaq Pharmaceuticals ETF FTXH | 0.36% | 130.7K | 0.60% |
| 8 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.32% | 73.4K | 1.22% |
| 9 | Franklin Genomic Advancements ETF HELX | 0.23% | 70.8K | 0.50% |
| 10 | First Trust Active Factor Small Cap ETF AFSM | 0.22% | 245.7K | 0.75% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.44
Bearish
Ratio by volume
2.02
Bullish
Buys
23
Sells
52
Shares acquired
627.8K
Shares disposed
310.4K
Cash buys
—
Cash sales
29.00
Net activity
+317,363
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | PYOTT DAVID E I | Director | M-Exempt | A | Common Stock | 1,383 | 0.00 | — | 1,383 | D | ↗ |
| 2026-03-20 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 2,989 | 66.75 | 199.5K | 82,791 | D | ↗ |
| 2026-03-19 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 4,174 | 67.00 | 279.7K | 35,028 | D | ↗ |
| 2026-03-19 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 4,231 | 67.00 | 283.5K | 63,959 | D | ↗ |
| 2026-03-19 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 4,589 | 67.00 | 307.5K | 85,780 | D | ↗ |
| 2026-03-19 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 4,440 | 67.00 | 297.5K | 61,480 | D | ↗ |
| 2026-03-19 | Lin Elizabeth Yeu | Officer | S-Sale | D | Common Stock | 390 | 67.00 | 26.1K | 23,308 | D | ↗ |
| 2026-03-19 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 2,186 | 67.00 | 146.5K | 43,316 | D | ↗ |
| 2026-03-19 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 11,964 | 67.00 | 801.6K | 33,421 | D | ↗ |
| 2026-03-18 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 4,071 | 68.71 | 279.7K | 39,202 | D | ↗ |
| 2026-03-18 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 4,125 | 68.71 | 283.4K | 68,190 | D | ↗ |
| 2026-03-18 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 3,610 | 68.71 | 248.0K | 90,369 | D | ↗ |
| 2026-03-18 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 4,330 | 68.71 | 297.5K | 65,920 | D | ↗ |
| 2026-03-18 | Lin Elizabeth Yeu | Officer | S-Sale | D | Common Stock | 379 | 68.71 | 26.0K | 23,698 | D | ↗ |
| 2026-03-18 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 2,133 | 68.71 | 146.6K | 45,502 | D | ↗ |
| 2026-03-18 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 11,667 | 68.71 | 801.6K | 45,385 | D | ↗ |
| 2026-03-17 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 4,029 | 69.42 | 279.7K | 43,273 | D | ↗ |
| 2026-03-17 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 4,084 | 69.42 | 283.5K | 72,315 | D | ↗ |
| 2026-03-17 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 3,125 | 69.42 | 216.9K | 93,979 | D | ↗ |
| 2026-03-17 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 4,286 | 69.42 | 297.5K | 70,250 | D | ↗ |
| 2026-03-17 | Lin Elizabeth Yeu | Officer | S-Sale | D | Common Stock | 375 | 69.42 | 26.0K | 24,077 | D | ↗ |
| 2026-03-17 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 2,111 | 69.42 | 146.5K | 47,635 | D | ↗ |
| 2026-03-17 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 10,972 | 69.42 | 761.7K | 57,052 | D | ↗ |
| 2026-03-16 | LINK WILLIAM J PHD | Director | S-Sale | D | Common Stock | 8,378 | 69.03 | 578.3K | 116,825 | D | ↗ |
| 2026-03-15 | Whitfield Dianne C. | Officer | M-Exempt | A | Common Stock | 23,909 | 0.00 | — | 47,302 | D | ↗ |
| 2026-03-15 | Wahl Bryan | Officer | M-Exempt | D | Restricted Stock Units | 5,022 | 0.00 | — | 15,067 | D | ↗ |
| 2026-03-15 | Neervannan Seshadri | Officer | M-Exempt | D | Restricted Stock Units | 5,097 | 0.00 | — | 0 | D | ↗ |
| 2026-03-15 | Mottiwala Aziz | Officer | M-Exempt | D | Restricted Stock Units | 8,148 | 0.00 | — | 8,148 | D | ↗ |
| 2026-03-15 | Lin Elizabeth Yeu | Officer | M-Exempt | D | Restricted Stock Units | 2,511 | 0.00 | — | 7,534 | D | ↗ |
| 2026-03-15 | Farrow Jeffrey S | Officer | M-Exempt | D | Restricted Stock Units | 5,022 | 0.00 | — | 15,067 | D | ↗ |
| 2026-03-15 | Azamian Bobak R. | Director / Officer | M-Exempt | D | Restricted Stock Units | 11,300 | 0.00 | — | 0 | D | ↗ |
| 2026-03-05 | Whitfield Dianne C. | Officer | A-Award | A | Restricted Stock Units | 17,161 | 0.00 | — | 17,161 | D | ↗ |
| 2026-03-05 | Wahl Bryan | Officer | A-Award | A | Restricted Stock Units | 17,161 | 0.00 | — | 17,161 | D | ↗ |
| 2026-03-05 | Neervannan Seshadri | Officer | A-Award | A | Stock Option (right to buy) | 27,310 | 74.90 | 2.05M | 27,310 | D | ↗ |
| 2026-03-05 | Mottiwala Aziz | Officer | A-Award | A | Restricted Stock Units | 19,306 | 0.00 | — | 19,306 | D | ↗ |
| 2026-03-05 | Lin Elizabeth Yeu | Officer | A-Award | A | Restricted Stock Units | 17,161 | 0.00 | — | 17,161 | D | ↗ |
| 2026-03-05 | Farrow Jeffrey S | Officer | A-Award | A | Restricted Stock Units | 19,306 | 0.00 | — | 19,306 | D | ↗ |
| 2026-03-05 | Azamian Bobak R. | Director / Officer | A-Award | A | Restricted Stock Units | 60,776 | 0.00 | — | 60,776 | D | ↗ |
| 2026-03-04 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 8,366 | 76.67 | 641.4K | 70,817 | D | ↗ |
| 2026-02-18 | PYOTT DAVID E I | Director | — | — | Stock Option (right to buy) | 2,500 | 18.27 | 45.7K | 0 | D | ↗ |
| 2026-01-02 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 5,715 | 80.09 | 457.7K | 33,243 | D | ↗ |
| 2025-12-24 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 5,443 | 82.41 | 448.6K | 858,548 | I | ↗ |
| 2025-12-16 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 7,397 | 80.10 | 592.5K | 38,958 | D | ↗ |
| 2025-12-16 | Neervannan Seshadri | Officer | G-Gift | D | Common Stock | 950 | 0.00 | — | 79,183 | D | ↗ |
| 2025-12-16 | Lin Elizabeth Yeu | Officer | S-Sale | D | Common Stock | 2,078 | 79.50 | 165.2K | 21,941 | D | ↗ |
| 2025-12-15 | Lin Elizabeth Yeu | Officer | M-Exempt | D | Restricted Stock Units | 6,819 | 0.00 | — | 20,459 | D | ↗ |
| 2025-12-15 | LINK WILLIAM J PHD | Director | S-Sale | D | Common Stock | 5,680 | 80.71 | 458.4K | 4,766 | I | ↗ |
| 2025-12-15 | Goodrich Katherine | Director | M-Exempt | A | Common Stock | 2,233 | 0.00 | — | 2,233 | D | ↗ |
| 2025-12-04 | Azamian Bobak R. | Director / Officer | G-Gift | D | Common Stock | 51,885 | 0.00 | — | 1,750 | D | ↗ |
| 2025-09-24 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 6,000 | 55.37 | 332.2K | 812,106 | I | ↗ |
| 2025-09-16 | LINK WILLIAM J PHD | Director | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 141,332 | D | ↗ |
| 2025-09-15 | Morrison Scott W | Director | M-Exempt | A | Common Stock | 1,334 | 0.00 | — | 4,684 | D | ↗ |
| 2025-09-08 | LINK WILLIAM J PHD | Director | S-Sale | D | Common Stock | 27,116 | 57.00 | 1.55M | 143,332 | D | ↗ |
| 2025-08-11 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 6,000 | 50.00 | 300.0K | 818,106 | I | ↗ |
| 2025-06-17 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 13,608 | 40.42 | 550.0K | 36,704 | D | ↗ |
| 2025-06-16 | Lin Elizabeth Yeu | Officer | S-Sale | D | Common Stock | 1,006 | 41.08 | 41.3K | 7,694 | D | ↗ |
| 2025-06-16 | Farrow Jeffrey S | Officer | M-Exempt | D | Restricted Stock Units | 27,881 | 0.00 | — | 55,763 | D | ↗ |
| 2025-06-13 | YARNO WENDY L | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | D | ↗ |
| 2025-06-13 | Morrison Scott W | Director | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 3,350 | D | ↗ |
| 2025-06-13 | Lin Elizabeth Yeu | Officer | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 8,700 | D | ↗ |
| 2025-06-13 | LINK WILLIAM J PHD | Director | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 170,448 | D | ↗ |
| 2025-06-13 | Goldberg Andrew D. | Director | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 16,700 | D | ↗ |
| 2025-06-13 | CHAUDHURI BHASKAR | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | D | ↗ |
| 2025-06-12 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 4,540 | 40.95 | 185.9K | 4,540 | D | ↗ |
| 2025-06-12 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 4,540 | 40.95 | 185.9K | 4,540 | D | ↗ |
| 2025-06-12 | LINK WILLIAM J PHD | Director | A-Award | A | Restricted Stock Units | 2,954 | 0.00 | — | 2,954 | D | ↗ |
| 2025-06-12 | Goodrich Katherine | Director | A-Award | A | Stock Option (right to buy) | 4,540 | 40.95 | 185.9K | 4,540 | D | ↗ |
| 2025-06-12 | Goldberg Andrew D. | Director | A-Award | A | Stock Option (right to buy) | 4,540 | 40.95 | 185.9K | 4,540 | D | ↗ |
| 2025-06-12 | CHAUDHURI BHASKAR | Director | A-Award | A | Stock Option (right to buy) | 4,540 | 40.95 | 185.9K | 4,540 | D | ↗ |
| 2025-06-09 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 17,500 | 43.76 | 765.8K | 47,557 | D | ↗ |
| 2025-03-24 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 6,000 | 50.00 | 300.0K | 824,106 | I | ↗ |
| 2025-03-20 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 2,137 | 50.11 | 107.1K | 46,355 | D | ↗ |
| 2025-03-20 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 3,084 | 50.11 | 154.5K | 51,712 | D | ↗ |
| 2025-03-20 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 2,435 | 50.11 | 122.0K | 79,682 | D | ↗ |
| 2025-03-20 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 3,365 | 50.11 | 168.6K | 65,057 | D | ↗ |
| 2025-03-20 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 1,186 | 50.11 | 59.4K | 22,431 | D | ↗ |
| 2025-03-20 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,534 | 50.11 | 427.6K | 53,635 | D | ↗ |
| 2025-03-19 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 2,259 | 47.40 | 107.1K | 48,492 | D | ↗ |
| 2025-03-19 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 3,261 | 47.40 | 154.6K | 54,796 | D | ↗ |
| 2025-03-19 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 2,543 | 47.40 | 120.5K | 82,117 | D | ↗ |
| 2025-03-19 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 3,557 | 47.40 | 168.6K | 68,422 | D | ↗ |
| 2025-03-19 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 1,254 | 47.40 | 59.4K | 23,617 | D | ↗ |
| 2025-03-19 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,551 | 47.40 | 405.3K | 62,169 | D | ↗ |
| 2025-03-18 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 2,315 | 46.29 | 107.2K | 50,751 | D | ↗ |
| 2025-03-18 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 3,341 | 46.29 | 154.7K | 58,057 | D | ↗ |
| 2025-03-18 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 2,605 | 46.29 | 120.6K | 84,660 | D | ↗ |
| 2025-03-18 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 3,643 | 46.29 | 168.6K | 71,979 | D | ↗ |
| 2025-03-18 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 1,284 | 46.29 | 59.4K | 24,871 | D | ↗ |
| 2025-03-18 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 7,131 | 46.29 | 330.1K | 70,720 | D | ↗ |
| 2025-03-17 | Farrow Jeffrey S | Officer | M-Exempt | D | Restricted Stock Units | 8,019 | 0.00 | — | 24,060 | D | ↗ |
| 2025-03-15 | Whitfield Dianne C. | Officer | M-Exempt | A | Common Stock | 18,885 | 0.00 | — | 53,066 | D | ↗ |
| 2025-03-15 | Wahl Bryan | Officer | M-Exempt | D | Restricted Stock Units | 4,790 | 0.00 | — | 4,790 | D | ↗ |
| 2025-03-15 | Neervannan Seshadri | Officer | M-Exempt | D | Restricted Stock Units | 5,097 | 0.00 | — | 5,097 | D | ↗ |
| 2025-03-15 | Mottiwala Aziz | Officer | M-Exempt | D | Restricted Stock Units | 4,790 | 0.00 | — | 4,790 | D | ↗ |
| 2025-03-15 | Farrow Jeffrey S | Officer | M-Exempt | A | Common Stock | 8,019 | 0.00 | — | 26,155 | D | ↗ |
| 2025-03-15 | Azamian Bobak R. | Director / Officer | M-Exempt | D | Restricted Stock Units | 11,299 | 0.00 | — | 11,300 | D | ↗ |
| 2025-03-07 | Goldberg Andrew D. | Director | M-Exempt | A | Common Stock | 7,000 | 12.89 | 90.2K | 13,350 | D | ↗ |
| 2025-03-05 | Whitfield Dianne C. | Officer | A-Award | A | Restricted Stock Units | 20,089 | 0.00 | — | 20,089 | D | ↗ |
| 2025-03-05 | Wahl Bryan | Officer | A-Award | A | Restricted Stock Units | 20,089 | 0.00 | — | 20,089 | D | ↗ |
| 2025-03-05 | Neervannan Seshadri | Officer | A-Award | A | Stock Option (right to buy) | 30,628 | 44.54 | 1.36M | 30,628 | D | ↗ |
| 2025-03-05 | Mottiwala Aziz | Officer | A-Award | A | Restricted Stock Units | 22,098 | 0.00 | — | 22,098 | D | ↗ |
| 2025-03-05 | Lin Elizabeth Yeu | Officer | A-Award | A | Restricted Stock Units | 10,045 | 0.00 | — | 10,045 | D | ↗ |
| 2025-03-05 | Farrow Jeffrey S | Officer | A-Award | A | Restricted Stock Units | 20,089 | 0.00 | — | 20,089 | D | ↗ |
| 2025-03-05 | Azamian Bobak R. | Director / Officer | A-Award | A | Restricted Stock Units | 59,512 | 0.00 | — | 59,512 | D | ↗ |
| 2024-11-13 | Goodrich Katherine | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.51 | 465.1K | 10,000 | D | ↗ |
| 2024-11-04 | Lin Elizabeth Yeu | Officer | A-Award | A | Stock Option (right to buy) | 41,074 | 46.21 | 1.90M | 41,074 | D | ↗ |
| 2024-09-30 | Morrison Scott W | Director | G-Gift | D | Common Stock | 6,016 | 0.00 | — | 0 | D | ↗ |
| 2024-09-15 | Morrison Scott W | Director | M-Exempt | D | Restricted Stock Units | 1,333 | 0.00 | — | 1,334 | — | ↗ |
| 2024-08-12 | LINK WILLIAM J PHD | Director | J-Other | A | Common Stock | 27,116 | 0.00 | — | 167,098 | — | ↗ |
| 2024-06-24 | YARNO WENDY L | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | — | ↗ |
| 2024-06-24 | Morrison Scott W | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | — | ↗ |
| 2024-06-24 | Lin Elizabeth Yeu | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | — | ↗ |
| 2024-06-24 | LINK WILLIAM J PHD | Director | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 139,982 | — | ↗ |
| 2024-06-24 | Goldberg Andrew D. | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | — | ↗ |
| 2024-06-24 | Crane Rosemary A | Director | M-Exempt | A | Common Stock | 3,350 | 0.00 | — | 5,350 | — | ↗ |
| 2024-06-24 | CHAUDHURI BHASKAR | Director | M-Exempt | D | Restricted Stock Units | 3,350 | 0.00 | — | 0 | — | ↗ |
| 2024-06-18 | Farrow Jeffrey S | Officer | S-Sale | D | Common Stock | 10,445 | 27.47 | 286.9K | 18,136 | — | ↗ |
| 2024-06-17 | Farrow Jeffrey S | Officer | M-Exempt | D | Restricted Stock Units | 27,881 | 0.00 | — | 83,644 | — | ↗ |
| 2024-06-13 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 33.14 | 165.7K | 5,000 | — | ↗ |
| 2024-06-13 | Morrison Scott W | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-06-13 | Lin Elizabeth Yeu | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-06-13 | LINK WILLIAM J PHD | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-06-13 | Goldberg Andrew D. | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-06-13 | Crane Rosemary A | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-06-13 | CHAUDHURI BHASKAR | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2024-03-18 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 4,314 | 30.60 | 132.0K | 34,181 | — | ↗ |
| 2024-03-18 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 4,436 | 30.60 | 135.7K | 40,951 | — | ↗ |
| 2024-03-18 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 4,879 | 30.60 | 149.3K | 64,767 | — | ↗ |
| 2024-03-18 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 4,766 | 30.60 | 145.8K | 54,075 | — | ↗ |
| 2024-03-18 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 10,415 | 30.60 | 318.7K | 26,456 | — | ↗ |
| 2024-03-15 | Whitfield Dianne C. | Officer | M-Exempt | D | Restricted Stock Units | 7,248 | 0.00 | — | 21,745 | — | ↗ |
| 2024-03-15 | Wahl Bryan | Officer | M-Exempt | A | Common Stock | 12,038 | 0.00 | — | 45,387 | — | ↗ |
| 2024-03-15 | Neervannan Seshadri | Officer | M-Exempt | A | Common Stock | 13,245 | 0.00 | — | 69,646 | — | ↗ |
| 2024-03-15 | Mottiwala Aziz | Officer | M-Exempt | D | Restricted Stock Units | 4,790 | 0.00 | — | 9,580 | — | ↗ |
| 2024-03-15 | Azamian Bobak R. | Director / Officer | M-Exempt | D | Restricted Stock Units | 11,299 | 0.00 | — | 22,599 | — | ↗ |
| 2024-03-07 | Whitfield Dianne C. | Officer | A-Award | A | Stock Option (right to buy) | 42,500 | 35.50 | 1.51M | 42,500 | — | ↗ |
| 2024-03-07 | Wahl Bryan | Officer | A-Award | A | Restricted Stock Units | 28,702 | 0.00 | — | 28,702 | — | ↗ |
| 2024-03-07 | Neervannan Seshadri | Officer | A-Award | A | Restricted Stock Units | 32,079 | 0.00 | — | 32,079 | — | ↗ |
| 2024-03-07 | Mottiwala Aziz | Officer | A-Award | A | Restricted Stock Units | 32,079 | 0.00 | — | 32,079 | — | ↗ |
| 2024-03-07 | Farrow Jeffrey S | Officer | A-Award | A | Restricted Stock Units | 32,079 | 0.00 | — | 32,079 | — | ↗ |
| 2024-03-07 | Azamian Bobak R. | Director / Officer | A-Award | A | Restricted Stock Units | 92,485 | 0.00 | — | 92,485 | — | ↗ |
| 2024-01-25 | Lin Elizabeth Yeu | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 26.25 | 262.5K | 10,000 | — | ↗ |
| 2023-12-27 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 20.22 | 161.8K | 830,106 | — | ↗ |
| 2023-12-20 | Trevejo Jose M. | Officer | S-Sale | D | Common Stock | 2,252 | 20.00 | 45.0K | 2,251 | — | ↗ |
| 2023-12-20 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 9,443 | 19.96 | 188.5K | 868,663 | — | ↗ |
| 2023-12-15 | Goldberg Andrew D. | Director | P-Purchase | A | Common Stock | 1,000 | 18.96 | 19.0K | 3,000 | — | ↗ |
| 2023-12-02 | YARNO WENDY L | Director | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 7,000 | — | ↗ |
| 2023-11-30 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 8,355 | 16.31 | 136.3K | 26,784 | — | ↗ |
| 2023-11-30 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 8,356 | 16.31 | 136.3K | 31,966 | — | ↗ |
| 2023-11-29 | Whitfield Dianne C. | Officer | M-Exempt | A | Common Stock | 23,920 | 0.00 | — | 35,139 | — | ↗ |
| 2023-11-29 | Wahl Bryan | Officer | M-Exempt | A | Common Stock | 23,920 | 0.00 | — | 40,322 | — | ↗ |
| 2023-11-15 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 4,904 | 18.54 | 90.9K | 878,306 | — | ↗ |
| 2023-10-18 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 13.24 | 105.9K | 886,106 | — | ↗ |
| 2023-10-05 | Trevejo Jose M. | Officer | S-Sale | D | Common Stock | 1,604 | 18.00 | 28.9K | 4,503 | — | ↗ |
| 2023-09-20 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 17.21 | 137.7K | 894,106 | — | ↗ |
| 2023-09-15 | Morrison Scott W | Director | M-Exempt | D | Restricted Stock Units | 1,333 | 0.00 | — | 2,667 | — | ↗ |
| 2023-08-23 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 17.23 | 137.8K | 902,106 | — | ↗ |
| 2023-08-15 | Lin Elizabeth Yeu | Director | P-Purchase | A | Common Stock | 9,506 | 16.80 | 159.7K | 15,866 | — | ↗ |
| 2023-07-19 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 2,400 | 20.05 | 48.1K | 45,806 | — | ↗ |
| 2023-07-19 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 99,726 | 20.04 | 2.00M | 910,106 | — | ↗ |
| 2023-07-12 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 9,000 | 17.35 | 156.2K | 1,014,006 | — | ↗ |
| 2023-06-22 | YARNO WENDY L | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-22 | Morrison Scott W | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-22 | Lin Elizabeth Yeu | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 17.99 | 90.0K | 5,000 | — | ↗ |
| 2023-06-22 | LINK WILLIAM J PHD | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-22 | Goldberg Andrew D. | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-22 | Crane Rosemary A | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-22 | CHAUDHURI BHASKAR | Director | A-Award | A | Restricted Stock Units | 3,350 | 0.00 | — | 3,350 | — | ↗ |
| 2023-06-21 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 18.63 | 149.0K | 1,023,006 | — | ↗ |
| 2023-06-16 | YARNO WENDY L | Director | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2023-06-16 | Lin Elizabeth Yeu | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | — | ↗ |
| 2023-06-16 | LINK WILLIAM J PHD | Director | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 136,632 | — | ↗ |
| 2023-06-16 | Goldberg Andrew D. | Director | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2023-06-16 | Crane Rosemary A | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | — | ↗ |
| 2023-06-16 | CHAUDHURI BHASKAR | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | — | ↗ |
| 2023-06-14 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 9,000 | 18.58 | 167.2K | 1,031,006 | — | ↗ |
| 2023-06-08 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 100 | 20.00 | 2.0K | 48,086 | — | ↗ |
| 2023-06-08 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 3,100 | 20.01 | 62.0K | 1,040,006 | — | ↗ |
| 2023-06-07 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 2,500 | 19.34 | 48.4K | 48,186 | — | ↗ |
| 2023-06-06 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 2,143 | 18.61 | 39.9K | 50,686 | — | ↗ |
| 2023-05-17 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 15.90 | 127.2K | 1,043,106 | — | ↗ |
| 2023-05-11 | LINK WILLIAM J PHD | Director | J-Other | A | Common Stock | 41,219 | 0.00 | — | 109,892 | — | ↗ |
| 2023-05-10 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 9,000 | 16.80 | 151.2K | 1,051,106 | — | ↗ |
| 2023-05-01 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 5,841 | 15.10 | 88.2K | 1,060,106 | — | ↗ |
| 2023-04-28 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 4,278 | 15.13 | 64.7K | 1,065,947 | — | ↗ |
| 2023-04-24 | Farrow Jeffrey S | Officer | A-Award | A | Stock Option (right to buy) | 163,397 | 14.62 | 2.39M | 163,397 | — | ↗ |
| 2023-04-21 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 2,311 | 15.03 | 34.7K | 1,070,225 | — | ↗ |
| 2023-04-20 | Greenstein Leonard M. | Officer | S-Sale | D | Common Stock | 5,000 | 14.02 | 70.1K | 26,785 | — | ↗ |
| 2023-04-19 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 8,000 | 13.60 | 108.8K | 1,072,536 | — | ↗ |
| 2023-03-23 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 345 | 12.15 | 4.2K | 11,219 | — | ↗ |
| 2023-03-23 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 371 | 12.15 | 4.5K | 16,402 | — | ↗ |
| 2023-03-23 | Trevejo Jose M. | Officer | S-Sale | D | Common Stock | 465 | 12.15 | 5.6K | 6,107 | — | ↗ |
| 2023-03-23 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 390 | 12.15 | 4.7K | 54,696 | — | ↗ |
| 2023-03-23 | Mottiwala Aziz | Officer | S-Sale | D | Common Stock | 372 | 12.15 | 4.5K | 52,829 | — | ↗ |
| 2023-03-23 | Greenstein Leonard M. | Officer | S-Sale | D | Common Stock | 346 | 12.15 | 4.2K | 31,785 | — | ↗ |
| 2023-03-23 | Azamian Bobak R. | Director / Officer | S-Sale | D | Common Stock | 737 | 12.15 | 9.0K | 8,597 | — | ↗ |
| 2023-03-22 | Whitfield Dianne C. | Officer | S-Sale | D | Common Stock | 333 | 12.64 | 4.2K | 11,564 | — | ↗ |
| 2023-03-22 | Wahl Bryan | Officer | S-Sale | D | Common Stock | 357 | 12.64 | 4.5K | 16,773 | — | ↗ |
| 2023-03-22 | Trevejo Jose M. | Officer | S-Sale | D | Common Stock | 529 | 12.64 | 6.7K | 6,572 | — | ↗ |
| 2023-03-22 | Neervannan Seshadri | Officer | S-Sale | D | Common Stock | 379 | 12.64 | 4.8K | 55,086 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-171.6K
Shares Outstanding
42.56M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Board Chairman | 726.3K | — | 2.65M | 2.65M | 555.7K | 36.2K | 6.62M | 80.08% | ↗ |
| 2 | 2025 | Aziz Mottiwala Chief Commercial Officer | 529.3K | — | 983.4K | 984.5K | 260.1K | 32.3K | 2.79M | 70.55% | ↗ |
| 3 | 2025 | Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer | 541.7K | — | 894.0K | 895.0K | 264.9K | 82.1K | 2.68M | 66.81% | ↗ |
| 4 | 2025 | Seshadri Neervannan, Ph.D. Chief Operating Officer | 547.0K | — | 894.0K | 895.0K | 267.3K | 24.9K | 2.63M | 68.07% | ↗ |
| 5 | 2025 | Bryan Wahl, M.D., J.D General Counsel | 500.8K | — | 894.0K | 895.0K | 245.5K | 24.9K | 2.56M | 69.88% | ↗ |
| 6 | 2024 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Board Chairman | 673.4K | — | 3.37M | 3.27M | 532.8K | 52.1K | 7.90M | 84.06% | ↗ |
| 7 | 2024 | Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer | 520.8K | — | 1.17M | 1.13M | 307.2K | 102.5K | 3.23M | 71.22% | ↗ |
| 8 | 2024 | Seshadri Neervannan, Ph.D. Chief Operating Officer | 527.3K | — | 1.17M | 1.13M | 311.3K | 53.7K | 3.19M | 72.07% | ↗ |
| 9 | 2024 | Aziz Mottiwala Chief Commercial Officer | 492.6K | — | 1.17M | 1.13M | 292.5K | 51.4K | 3.14M | 73.35% | ↗ |
| 10 | 2024 | Elizabeth Yeu-Lin, M.D. Chief Medical Officer | 78.2K | 25.0K | 1.40M | 1.55M | — | 53.5K | 3.10M | 94.95% | ↗ |
| 11 | 2023 | Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer | 343.8K | 100.0K | 1.68M | 1.59M | 241.2K | 38.0K | 3.99M | 81.89% | ↗ |
| 12 | 2023 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Board Chairman | 619.5K | — | 1.03M | 1.02M | 450.3K | 13.2K | 3.13M | 65.40% | ↗ |
| 13 | 2023 | Leonard Greenstein Chief Financial Officer | 202.1K | — | 411.7K | 893.3K | 71.6K | 399.9K | 1.98M | 65.96% | ↗ |
| 14 | 2023 | Seshadri Neervannan, Ph.D. Chief Operating Officer | 500.0K | — | 494.1K | 488.6K | 246.0K | 13.2K | 1.74M | 56.42% | ↗ |
| 15 | 2022 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Board Chairman | 590.0K | — | 876.8K | 2.08M | 324.5K | 47.6K | 3.92M | 75.43% | ↗ |
| 16 | 2022 | Jose Trevejo, M.D., Ph.D Chief Medical Officer | 403.3K | 150.0K | 606.1K | 1.64M | 176.0K | 40.1K | 3.02M | 74.50% | ↗ |
| 17 | 2022 | Bryan Wahl, M.D., J.D. General Counsel and Secretary | 420.0K | — | 1.03M | 880.6K | 168.0K | 31.1K | 2.53M | 75.57% | ↗ |
| 18 | 2021 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Board Chairman | 550.0K | — | — | 6.03M | 269.5K | 21.6K | 6.87M | 87.76% | ↗ |
| 19 | 2021 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Director | 550.0K | 269.5K | — | 6.03M | — | 21.6K | 6.87M | 87.76% | ↗ |
| 20 | 2021 | Dianne Whitfield, MSW Chief Human Resources Officer | 358.6K | 194.6K | — | 2.63M | — | 25.7K | 3.21M | 81.95% | ↗ |
| 21 | 2021 | Bryan Wahl, M.D., J.D. General Counsel and Secretary | 345.0K | 50.0K | — | 2.08M | 141.4K | 9.1K | 2.63M | 79.23% | ↗ |
| 22 | 2020 | Bobak Azamian, M.D., Ph.D. President, Chief Executive Officer and Director | 437.0K | 211.5K | — | 1.85M | — | 14.8K | 2.51M | 73.58% | ↗ |
| 23 | 2020 | Bobak Azamian, M.D. Ph.D. President, Chief Executive Officer and Director | 437.0K | 211.5K | — | 1.85M | — | 14.8K | 2.51M | 73.58% | ↗ |
| 24 | 2020 | Seshadri Neervannan, Ph.D. Chief Operating Officer | 199.6K | 85.2K | — | 1.93M | — | 2.2K | 2.21M | 87.03% | ↗ |
| 25 | 2020 | Leo Greenstein Chief Financial Officer | 256.0K | 147.4K | — | 418.7K | — | 13.3K | 835.4K | 50.12% | ↗ |
| 26 | 2019 | Bobak Azamian, M.D. Ph.D. President, Chief Executive Officer and Director | 300.0K | 116.1K | — | — | — | — | 416.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman | 1M | — |
| Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer | 930.6K | male |
| Seshadri Neervannan | Chief Operating Officer | 839.2K | — |
| Aziz Mottiwala | Chief Commercial Officer | 836.5K | male |
| Bryan Wahl | General Counsel & Corporate Secretary | 619.1K | — |
| Dianne C. Whitfield | Chief Human Resources Officer | 578.9K | female |
| Elizabeth Yeu | Chief Medical Officer | 156.7K | — |
| David Nakasone | Head of Investor Relations | — | male |
| Adrienne Kemp | Senior Director of Corporate Communications | — | female |
| Neera Clase | Senior Vice President of Market Access | — | female |
| Scott Youmans | Vice President of Sales | — | male |
| Cara Miller | Senior Vice President of Corporate Affairs | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TARS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
